HOME - Companies - Products
 
 
19 February 2025

TriAgenics Adds 20th International Patent to its Medical Device Portfolio


TriAgenics, the pioneer of fully guided tooth bud ablation, has announced the grant of four additional European patents, further establishing the company’s global IP position for a novel technology designed to prevent third molar formation. Germany, France, Italy, and the United Kingdom are the latest European countries to grant a patent for TriAgenics’ ablation probe system.

TriAgenics’ patented micro-ablation technology is the cornerstone behind Zero3 TBA, a preventive-care treatment for children ages 6–12. The treatment prevents the formation of third molars through the application of low-level, CT-guided microwave energy. This new dental modality is based on microwave ablation techniques commonly used in the medical field. TriAgenics plans to introduce Zero3 TBA to the U.S. dental market in 2025, following clearance from the U.S. Food and Drug Administration.

Following FDA clearance, dentists will send patient CBCT and intraoral scans to TriAgenics, which will fabricate custom Zero3 kits and ship them to dentists to perform the one-minute treatment using TriAgenics’ proprietary ablation technology.

TriAgenics believes the economic impact of Zero3 TBA treatment will be massive. Total expenditures associated with extracting third molars and correcting related problems are estimated to be nearly $5 billion in the U.S. alone.

TriAgenics estimates its total addressable market will be greater than $2.5 billion annually when Zero3 TBA treatment becomes the new standard of care in the U.S.

About TriAgenics

TriAgenics is a disruptive oral healthcare company that has pioneered the development of a one-minute treatment designed to prevent third molars from ever forming. Based on extensive animal trials, TriAgenics’ Zero3 TBA system is expected to eliminate all pain and complications normally associated with third molar extraction. TriAgenics’ mission is to provide dentists and their patients with a non-surgical alternative that has no painful recovery or need to miss work or school.


Source: www.triagenics.com

Related articles

TriAgenics, Inc., a privately held company pioneering a non-surgical approach to third molar (wisdom tooth) prevention, today announced that it expanded its Series B-1 funding round in response to...


News     05 May 2025

TriAgenics Appoints New CEO

TriAgenics, Inc., pioneer of Zero3 TBA, a fully guided tooth bud ablation system designed to prevent third molar formation, announced that David Thrower has been named president and CEO.


Fairbanks Dental Associates announces the addition of Dr. Kimball Spencer to its team of dental professionals serving the Temple and Belton, Texas communities.


News     01 September 2025

USOSM Adds Four New Partner Practices

U.S. Oral Surgery Management (USOSM)—a management services organization that exclusively serves premier oral and maxillofacial surgeons—has secured partnerships with four new practices, including...


PDS Health Technologies, a business unit of PDS Health, announced today that it has completed an agreement to offer SOTA Cloud as part of its integrated health technology services. 


Read more

Much like EMTs rushing to the scene after an accident, stem cells hurry to the site of a skull fracture to start mending the damage. A new finding has uncovered the signaling mechanism that triggers...


SimplyTest has launched a groundbreaking saliva-based test to detect high-risk strains of oral human papillomavirus (HPV), a major cause of oropharyngeal cancers.


Perimetrics, Inc., a dental technology company pioneering quantitative diagnostics, announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for the InnerView...


On October 15, open enrollment for Medicare began nationwide. Hundreds of thousands of seniors in New Jersey will once again face the challenge of finding the right Medicare coverage, including the...


 
 
 
 

 
 
 
 

Most popular

 
 

Events